Trevogrumab: Phase 2 Combination Studies# Regeneron announced Phase 2 results in September 2025 evaluating trevogrumab in combination with semaglutide, with and without garetosmab (anti-activin A)
Factors, such as mitochondrial overdrive and calcium dysregulation, contribute to cisplatin-induced ototoxicity and noise-induced hearing loss
This is how the medication works
Es importante llevar una dieta variada y equilibrada y un estilo de vida saludable
This increase in urination linked to weight loss is usually short-lived
doi: 10.3389/fphar.2025.1602976 Received 30 March 2025 Revised 13 November 2025 Accepted 14 November 2025 Published 19 December 2025 Volume 16 - 2025 Edited by Bernd Rosenkranz, Fundisa African Academy of Medicines Development, South Africa Reviewed by Kacper Nijakowski, Poznan University of Medical Sciences, Poland Miriam Njoki Karinja, Science for Africa Foundation, Kenya Updates Copyright 2025 Mazur, Ndokaj, Salerno, Vallone, Ardan, Bietolini, Carrouel, Wilk, Sarig, Ottolenghi and Bourgeois
